Drugs / Botulinum toxin
Botulinum toxin
also known as
Botox · QM1114-DP · Botulinum neurotoxin · BoNT · BTx · BTX A · Botulinum toxin A · Dysport · +8 more
Trials 53 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05062902 | Sep 2025 → Aug 2027 expected | chronic pain syndrome, interstitial cystitis, pelvis syndrome | HillMed Inc. | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04523506 | May 2020 → Apr 2021 | scleroderma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06796985 | Feb 2025 → Mar 2027 expected | — | University of Miami | Recruiting | No outcome recorded |
| Phase 1 | NCT04630873 | Nov 2020 → Aug 2025 overdue | spastic hemiplegia | University of Ioannina | Recruiting | No outcome recorded |
| Phase 1 | NCT04030767 | Sep 2019 → Sep 2020 | gingival overgrowth | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT02139319 | Mar → Jul 2014 | osteoarthritis, knee | Galderma R&D | Completed | No outcome recorded |
| Phase 1 | NCT02003027 | Jun 2013 → Dec 2015 | — | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 1 | NCT02003001 | Jun 2013 → Mar 2016 | ventricular tachycardia | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 1 | NCT01682733 | Aug 2012 → Dec 2014 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00767546 | May 2009 → Aug 2010 | Parkinson disease, seborrheic dermatitis | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05012566 | Jul 2021 → Jul 2023 | facial paralysis | Azienda Ospedaliera Universitaria Integrata Verona | Unknown | No outcome recorded |
| Phase 2 | NCT04409600 | Nov 2020 → Dec 2024 | compartment syndrome | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02982434 | Sep 2016 → Dec 2017 | atrial fibrillation, ischemic disease | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02623829 | Dec 2015 → Mar 2019 | keloid formation | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02867787 | Mar 2014 → Sep 2016 | rotator cuff syndrome | Versailles Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01955174 | Aug 2013 → May 2017 | esophageal disorder | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT00973999 | Sep 2009 → Sep 2011 | traumatic brain injury | HCA International Limited | Withdrawn | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT05478551 | Jun 2022 → Dec 2026 expected | reactive cutaneous fibrous lesion | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03339921 | Dec 2018 → May 2020 | compartment syndrome | 375th Medical Group, Scott Air Force Base | Terminated | No outcome recorded |
| Phase 2/3 | NCT02617069 | Sep 2015 → Mar 2016 | atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2/3 | NCT01780636 | Jan 2013 → Jan 2014 | anismus | Karen Noblett | Terminated | No outcome recorded |
| Phase 2/3 | NCT00133861 | Apr 2005 → Jun 2008 | cerebral palsy | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT05998187 | Apr 2025 → Jun 2027 expected | — | University Hospital, Rouen | Recruiting | No outcome recorded |
| Phase 3 | NCT05008731 | Jul 2024 → Feb 2026 | congenital contractures | Ramsay Santé | Terminated | No outcome recorded |
| Phase 3 | NCT05990881 | Aug 2023 → Dec 2025 overdue | carpal displacement, salivary substance, Clostridium botulinum type, thumb deformity | Rhode Island Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05148000 | Jan → Mar 2023 | eyelid disorder | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT05463965 | Jul 2022 → Jan 2023 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04249583 | Feb → Aug 2020 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04247074 | Feb → Oct 2020 | disease of orbital part of eye adnexa | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04249687 | Feb → Sep 2020 | eyelid disorder | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04225260 | Jan 2020 → Apr 2021 | eyelid disorder | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04579419 | Nov 2019 → Aug 2020 | — | King Abdulaziz Medical City | Completed | No outcome recorded |
| Phase 3 | NCT01829763 | Apr 2013 → Apr 2015 | hemiplegia | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 3 | NCT01422161 | Apr 2010 → Oct 2015 | stroke disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06411028 | Jan 2025 → May 2027 expected | dystonic disorder | Radboud University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06734598 | Dec 2024 → Nov 2025 overdue | head and neck cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06080438 | Nov 2022 → Jul 2024 | excessive tearing, eyelid disorder | University of Miami | Terminated | No outcome recorded |
| Phase 4 | NCT04829565 | Sep 2021 → May 2025 overdue | arthropathy, erosive | Centre Hospitalier Universitaire de Nice | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03701919 | Jan 2019 → Nov 2022 | — | Albany Medical College | Completed | No outcome recorded |
| Phase 4 | NCT02786550 | Jun 2016 → Jun 2018 | eyelid degenerative disorder | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00119886 | Apr 2005 → Jun 2008 | vulvar disease, vulvodynia | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07180394 | Sep 2025 → Aug 2030 expected | strabismus | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07025642 | Jul 2025 → May 2026 overdue | overactive bladder | Mackay Medical College | Recruiting | No outcome recorded |
| — | NCT06733025 | Jan 2025 → Jan 2029 expected | spinal cord injury, stroke disorder, traumatic brain injury | Vastra Gotaland Region | Recruiting | No outcome recorded |
| — | NCT06593821 | Apr 2023 → Jan 2024 | bruxism, masticatory muscles, hypertrophy of | Zonguldak Bulent Ecevit University | Completed | No outcome recorded |
| — | NCT07124806 | Jul → Nov 2022 | movement disorder, spastic hemiplegia, stroke disorder | Universidad de los Andes, Chile | Completed | No outcome recorded |
| — | NCT04177186 | Oct 2020 → Aug 2021 | cerebral palsy spastic hemiplegic, spastic diplegia | Asir John Samuel | Unknown | No outcome recorded |
| — | NCT03938363 | Oct 2019 → Jun 2022 | benign essential blepharospasm, cervical dystonia | University Hospital, Grenoble | Completed | No outcome recorded |
| — | NCT03836638 | May 2019 → Dec 2020 | salivary substance, Clostridium botulinum type | St Joseph University, Beirut, Lebanon | Unknown | No outcome recorded |
| — | NCT03247868 | Mar 2016 → Mar 2018 | cervical dystonia | Fondazione Don Carlo Gnocchi ETS | Unknown | No outcome recorded |
| — | NCT02244671 | Jan 2014 → Jan 2018 | eye adnexa disorder | Fox, Donald Munro, M.D., P.C. | Completed | No outcome recorded |
| — | NCT01631604 | Jun 2012 → Jun 2017 | movement disorder | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT03405948 | May 2006 → May 2009 | clubfoot | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04439825 Comparator | Jul → Sep 2020 | — | DeNova Research | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02015039 Background | Dec 2013 → Sep 2016 | focal, segmental or multifocal dystonia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02008448 Comparator | Jun 2013 → Dec 2015 | persistent atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02008461 Comparator | Jun 2013 → Dec 2015 | cardiac rhythm disease | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02002923 Comparator | Jun 2013 → Jun 2015 | paroxysmal atrial fibrillation, persistent atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT01842529 Comparator | Sep 2012 → Dec 2013 | paroxysmal atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Completed | No outcome recorded |
| Phase 2 | NCT00701233 Comparator | Jun 2012 → Oct 2018 | carpal tunnel syndrome | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT00015457 Background | Apr 2001 → Apr 2009 | focal dystonia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05146999 Comparator | May → Oct 2022 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01586819 Comparator | Sep 2011 → May 2013 | — | Loyola University | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05125029 Comparator | Feb 2022 → Dec 2025 overdue | Raynaud disease | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT03302741 Background | Nov 2017 → Nov 2019 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02361749 Comparator | Sep 2014 → Aug 2018 | constipation disorder | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT02472210 Comparator | Jul 2014 → Jul 2015 | Parkinson disease | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT01032954 Comparator | Nov 2009 → Dec 2010 | — | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07057050 Background | Jun → Oct 2025 | stroke disorder | Cairo University | Completed | No outcome recorded |
| — | NCT06583551 Comparator | Jan → Mar 2021 | bruxism | University of Health Sciences | Completed | No outcome recorded |
| — | NCT03546959 Background | Jun 2018 → Feb 2019 | stroke disorder | Marmara University | Completed | No outcome recorded |
| — | NCT02711995 Comparator | Dec 2015 → Sep 2016 | essential tremor | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT00845897 Comparator | Mar 2005 → Mar 2010 | diabetes mellitus, peripheral neuropathy, ulcer of lower limbs | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00927849 Comparator | Sep 2002 → Apr 2008 | rectal disorder | Mansoura University | Completed | No outcome recorded |
Press releases naming this drug 43 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-04 | AbbVie | Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence abbvie.com ↗ |
| 2026-07-09 | Ipsen | Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. ipsen.com ↗ |
| 2026-06-24 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 abbvie.com ↗ |
| 2026-05-19 | Ipsen | Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity ipsen.com ↗ |
| 2026-04-08 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year abbvie.com ↗ |
| 2025-10-29 | AbbVie | The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year abbvie.com ↗ |
| 2025-10-06 | AbbVie | AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor abbvie.com ↗ |
| 2025-09-09 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories abbvie.com ↗ |
| 2024-11-07 | AbbVie | Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day abbvie.com ↗ |
| 2024-10-18 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) abbvie.com ↗ |
| 2024-09-24 | AbbVie | Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns abbvie.com ↗ |
| 2024-09-11 | AbbVie | Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China abbvie.com ↗ |
| 2024-06-11 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients abbvie.com ↗ |
| 2024-04-23 | AbbVie | Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands abbvie.com ↗ |
| 2024-02-21 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs abbvie.com ↗ |
| 2023-11-20 | AbbVie | Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever abbvie.com ↗ |
| 2023-11-01 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before abbvie.com ↗ |
| 2023-09-18 | AbbVie | Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence abbvie.com ↗ |
| 2023-09-06 | AbbVie | Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs abbvie.com ↗ |
| 2023-08-30 | AbbVie | Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic) abbvie.com ↗ |
| 2023-08-23 | Ipsen | TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications ipsen.com ↗ |
| 2023-06-13 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program abbvie.com ↗ |
| 2023-03-08 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs abbvie.com ↗ |
| 2022-11-17 | AbbVie | Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet abbvie.com ↗ |
| 2022-11-02 | AbbVie | Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day abbvie.com ↗ |
| 2022-09-13 | AbbVie | Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories abbvie.com ↗ |
| 2022-06-09 | Ipsen | Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury ipsen.com ↗ |
| 2022-04-13 | AbbVie | BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval abbvie.com ↗ |
| 2022-01-24 | AbbVie | Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA) abbvie.com ↗ |
| 2021-11-15 | AbbVie | Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day abbvie.com ↗ |
| 2021-07-29 | AbbVie | FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity abbvie.com ↗ |
| 2021-06-08 | AbbVie | Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign abbvie.com ↗ |
| 2021-02-10 | AbbVie | BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition abbvie.com ↗ |
| 2020-11-16 | AbbVie | Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day abbvie.com ↗ |
| 2020-07-09 | AbbVie | FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗ |
| 2020-06-22 | AbbVie | FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity abbvie.com ↗ |
| 2020-05-23 | Ipsen | New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence ipsen.com ↗ |
| 2020-01-06 | Ipsen | Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy ipsen.com ↗ |
| 2019-09-23 | Ipsen | Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis ipsen.com ↗ |
| 2019-06-21 | AbbVie | FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity abbvie.com ↗ |
| 2019-03-07 | AbbVie | FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity abbvie.com ↗ |
| 2019-01-28 | AbbVie | New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand abbvie.com ↗ |
| 2018-09-14 | AbbVie | Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines abbvie.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 78 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botulinum toxin | “The aim of this prospective non-randomized study was to assess the efficacy and safety of endomyocardial botulinum toxin injection in left ventricle for preventing episodes of VT Storm.” NCT02003027 ↗62“While Botulinum toxin(BoNT) injections are widely used for focal spasticity, surgical interventions remain underutilized despite promising long-term outcomes.” NCT06733025 ↗ “Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).” NCT02008448 ↗ “This project aims to explore the therapeutic effect of Botulinum toxin (Botox) injection to the masticatory muscles in the above-mentioned patients.” NCT06734598 ↗ “Local injection of Botulinum toxin (BTx) has become a mainstay of the treatment of focal spasticity, particularly in post-stroke patients.” NCT01829763 ↗ “The investigators assume that intramuscular injection of botulinum toxin is effective in the treatment of tendinopathy rotator cuff.” NCT02867787 ↗ “Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity” NCT04030767 ↗ “Botulinum toxin treatment results in a pharmacologic recession of the injected extraocular muscle” NCT07180394 ↗ “Focal injections of botulinum toxin (BoNT) are the current best therapy.” NCT02015039 ↗ “Botulinum Toxin diluted in Sodium Bicarbonate” NCT04579419 ↗ “Botulinum toxin” NCT01631604 ↗ |
| Known as | BoNT | “The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat...” NCT05062902 ↗3“While Botulinum toxin(BoNT) injections are widely used for focal spasticity, surgical interventions remain underutilized despite promising long-term outcomes.” NCT06733025 ↗ “Focal injections of botulinum toxin (BoNT) are the current best therapy.” NCT02015039 ↗ “Botulinum neurotoxin (BoNT) is the first-line treatment of ICD” PMID 31478151 ↗ Sep 2019 |
| Known as | BoNTA | “intradetrusor injection of botulinum neurotoxin type A (BoNTA)” NCT07025642 ↗ |
| Known as | Botox | “This project aims to explore the therapeutic effect of Botulinum toxin (Botox) injection to the masticatory muscles in the above-mentioned patients.” NCT06734598 ↗6“Botulinum toxin (BTX, brand name Botox®), produced naturally by the bacterium Clostridium botulinum and adapted for medical use” NCT03701919 ↗ “Urodynamic evaluation before and after Botulinum toxin (Botox) injection.” NCT07025642 ↗ “A single session of Botox (Botulinum toxin A) injection was performed.” NCT06583551 ↗ “one hundred units of type A botulinum toxin (Botox®, Allergan)” NCT01955174 ↗ “Botulinum Toxin commonly known as BOTOX®” NCT01422161 ↗ “Biological: Botulinum toxin(Botox)” NCT04523506 ↗ |
| Known as | Botulin toxin | “patients with spastic hemiparesis which will be treated with Botulin toxin at different dilutions.” NCT04630873 ↗ |
| Known as | Botulinum neurotoxin | “Botulinum neurotoxin (BoNT) is the first-line treatment of ICD” PMID 31478151 ↗ Sep 2019 |
| Known as | botulinum neurotoxin type A | “intradetrusor injection of botulinum neurotoxin type A (BoNTA)” NCT07025642 ↗ |
| Known as | Botulinum toxin A | “A single session of Botox (Botulinum toxin A) injection was performed.” NCT06583551 ↗1“Botulinum toxin A injection” NCT00701233 ↗ |
| Known as | Botulinum Toxin Type A | “Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease” NCT02472210 ↗ |
| Known as | BTx | “Local injection of Botulinum toxin (BTx) has become a mainstay of the treatment of focal spasticity, particularly in post-stroke patients.” NCT01829763 ↗3“Botulinum toxin (BTX, brand name Botox®), produced naturally by the bacterium Clostridium botulinum and adapted for medical use” NCT03701919 ↗ “Improvement of cervical/eyelid control following botulinum toxin (BTX) injections would translate into gait changes.” PMID 38386480 ↗ Dec 2023 “Botulinum neurotoxin (BTX)” NCT03302741 ↗ |
| Known as | BTX A | “The study aimed to assess and compare the effectiveness of 4 different methods in the management bruxism: Botulinum toxin (BTX-A), dry needling (DN), pharmacological therapy...” NCT06583551 ↗2“OBJECTIVE: To determine the effects of botulinum neurotoxin type A (BTX-A) dilution and endplate-targeting in spastic elbow flexors.” PMID 19154823 ↗ Jan 2009 “botulinum toxin injection (BTX A)” NCT06411028 ↗ |
| Known as | Dysport | “A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient” NCT00927849 ↗1“Botulinum Toxin type-A (Dysport, Ipsen Ltd, Slough, Berkshire)” NCT00973999 ↗ |
| Known as | incobotulinumtoxin A | “All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH \& Co KGaA, Germany; 50 U/1 mL at...” NCT01842529 ↗ |
| Known as | Intramuscular injection of Botulinum toxin A. (BoNT-A) | “Intramuscular injection of Botulinum toxin A. (BoNT-A)” NCT06583551 ↗ |
| Known as | QM1114-DP | “The investigational product (QM1114-DP) is a BoNT Type A.” NCT04225260 ↗5“QM1114-DP, a Botulinum Toxin Type A (BoNT-A)” NCT04247074 ↗ “QM1114-DP, a Botulinum Toxin Type A (BoNT-A)” NCT04249583 ↗ |
| Known as | Vistabex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05012566 ↗ |
| Known as | Xeomin | “Patients with history of paroxysmal atrial fibrillation and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin, Merz, Germany; 50...” PMID 26486855 ↗ Oct 2015 |
| Action | Inhibit | “botulinium toxin, which inhibitis acetyl choline realese” NCT00767546 ↗ |
| Modality | Protein / enzyme biologic | “Biological: botulinum toxin injection” NCT01842529 ↗ |
| Route | Other | “after local injection with Botox” NCT00119886 ↗ |